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Abstract
TNF-a is a major cytokine implicated in rheumatoid arthritis. Its expression is regulated both at the transcriptional and
posttranscriptional levels and recent data demonstrated that miRNAs are implicated in TNF-a response in macrophages.
LPS-activated FLS isolated from RA patients express TNF-a mRNA but not the mature protein. This prompted us to look for
miRNAs which could be implicated in this anti-inflammatory effect. Using a microarray, we found two miRNAs, miR-125b
and miR-939 predicted to target the 39-UTR of TNF-a mRNA, to be up-regulated in RA FLS in response to LPS, but their
repression did not restore mature TNF-a expression in FLS. We showed previously that miR-346, which is upregulated in
LPS-activated FLS, inhibited Btk expression that stabilized TNF-a mRNA. Blocking miR-346 reestablished TNF-a expression in
activated FLS. Interestingly, transfection of miR-346 in LPS-activated THP-1 cells inhibited TNF-a secretion. We also
demonstrated that TTP, a RNA binding protein which inhibited TNF-a synthesis, is overexpressed in activated FLS and that
inhibition of miR-346 decreases its expression. Conversely, transfection of miR-346 in LPS-activated THP-1 cells increased
TTP mRNA expression and inhibited TNF-a release. These results indicate that miR-346 controls TNF-a synthesis by
regulating TTP expression.
Citation: Semaan N, Frenzel L, Alsaleh G, Suffert G, Gottenberg J-E, et al. (2011) miR-346 Controls Release of TNF-a Protein and Stability of Its mRNA in
Rheumatoid Arthritis via Tristetraprolin Stabilization. PLoS ONE 6(5): e19827. doi:10.1371/journal.pone.0019827
Editor: Joseph El Khoury, Massachusetts General Hospital and Harvard Medical School, United States of America
Received January 3, 2011; Accepted April 5, 2011; Published May 17, 2011
Copyright:  2011 Semaan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by an ATIP starting grant from CNRS to Se´bastien Pfeffer and by grants from Bristol Myers Squibb, Roche, Pfizer, Courtin
Fundation and CAMPLP to Dominique Wachsmann. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: Pr. Dominique Wachsmann’s work is supported by grants from Bristol Myers Squibb, Roche, Pfizer, Courtin Fundation and CAMPLP. Dr.
Pfeffer’s work is supported by ANR and the Ligue contre le Cancer. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and
materials.
* E-mail: s.pfeffer@ibmc-cnrs.unistra.fr (SP); dominique.wachsmann@pharma.u-strasbg.fr (DW)
. These authors contributed equally to this work.
Introduction
One of the key players in rheumatoid arthritis (RA) is TNF-a
and therapies targeting this cytokine have already proved
beneficial [1]. In RA, TNF-a is produced by many cell types,
mainly by macrophages and dendritic cells in response to
interactions between pathogen-associated molecular patterns
(PAMPs) or damage-associated molecular patterns (DAMPs)
and pattern-recognition receptors (PRRs) or to the cytokine
environment [2].
The resident cells of the joint space, the fibroblast-like
synoviocytes (FLS,) play a crucial role in RA [3,4,5]. They are
implicated in the inflammatory response essentially by synthesizing
cytokines, chemokines, prostanoids, nitric oxyde (NO), and pro-
angiogenic factors FLS play a key role in osteoarticular destruction
and take also part in the differentiation and activation of
osteoclasts by the RANK-RANK ligand pathway, and through
the release of PGE-2 and IL-6 [6,7,8]. However RA FLS secrete
no TNF-a, a major cytokine implicated in RA [9], but intriguingly
they express TNF-a mRNA in response to LPS. This was also
observed with osteoarthritis (OA) and trauma FLS (unpublished
data). It was therefore of interest to identify the molecular basis of
this anti-inflammatory mechanism. Post-transcriptional regulation
of TNF-a expression depends on AU-rich elements (ARE) located
in the 39-untranslated region (UTR) of TNF-a mRNA. RNA
binding proteins such as tristetraprolin (TTP), T-cell intracellular
antigen (TIA-1) and T-cell intracellular antigen-related protein
(TIAR) can bind to ARE of TNF-a mRNA inducing mRNA
lability or inhibition of translation [10,11]. Mice lacking TTP
develop a systemic inflammatory syndrome characterized by
cachexia, dermatitis, erosive arthritis and myeloid hyperplasia
[12]. Besides the direct destabilization of mRNA by regulatory
proteins, another mode of regulation involves miRNAs [13].
MiRNAs are an evolutionarily conserved class of endogenous
small non-coding RNAs. They are processed from long primary
transcripts by the ribonuclease Drosha in association with
DGCR8. After being transported into the cytoplasm, the pre-
miRNA is further processed by Dicer and its cofactor TRBP. One
strand is then assembled in the RISC complex which always
contains a member of the Argonaute family. The miRNA then
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guides the RISC complex to its target 39-UTR leading to a
decrease of mRNA stability or inhibition of translation [14,15].
Regulation of miRNAs expression is controlled at the level of
transcription, processing and subcellular localization and several
recent studies have indicated that these processes can be
influenced by factors such as inflammation [16,17]. Since their
discovery, miRNAs have been implicated in a wide array of
cellular and developmental processes and emerging data have
identified an important contribution of miRNAs to the develop-
ment and control of the inflammatory response [18–21]. For
example, Tili et al. [22] demonstrated that up-regulation of miR-
155 in LPS-activated macrophages resulted in an enhanced
translation of TNF-a mRNA. Mice overexpressing miR-155
produce more TNF-a when challenged with LPS. By contrast,
they found miR-125 to be implicated in the posttranscriptional
repression of TNF-a mRNA, hence the need for its down-
regulation for TNF-a production. A negative correlation between
miR-146a expression and TNF-a release was also demonstrated in
THP-1 cells [23,24]. These data indicate that miRNAs can exert
both negative as well as positive effects in inflammatory pathways
and this prompted us to look for miRNAs which could be
implicated in the anti-inflammatory effect of LPS in RA FLS. We
found two miRNAs, miR-125b and miR-939, which were
predicted to target the 39-UTR of TNF-a mRNA, to be up-
regulated in RA FLS in response to LPS, but their repression did
not restore either intracellular expression of TNF-a or its release
by LPS-activated FLS. We further demonstrated that inhibition of
miR-346, a negative regulator of Bruton’s tyrosine kinase (Btk)
expression, reestablished mature TNF-a expression in LPS-
activated FLS by blocking TTP expression. In parallel, over-
expression of miR-346 in LPS-activated THP-1 cells increased the
expression of TTP which resulted in inhibition of TNF-a synthesis.
These results indicate that miR-346 controls TNF-a synthesis by
regulating TTP expression and can therefore act as a negative
regulator of inflammation.
Results
LPS does not induce TNF-a production by RA FLS
We first confirmed that TNF-a was not released by FLS in
response to LPS. FLS (5. 105 cells) were activated with LPS from
Salmonella abortus equi (1 mg/ml) for 3 h, 6 h and 24 h and
activated-cells supernatants were analyzed by ELISA. Although
LPS stimulation induced IL-6 secretion (Figure 1A), activated FLS
did not release any detectable amount of mature TNF-a in cell
culture supernatants (Figure 1B). THP-1 cells were used as a
positive control: upon LPS treatment, a high accumulation of
TNF-a was found in cell culture supernatants with values reaching
2400 pg/ml (6 h) representing a five-fold increase compared to
control (C) (Figure 1C). Finally, we demonstrated by western
blotting that non-activated or LPS-activated FLS did not express
the mature protein (Figure 1D).
Figure 1. Effect of LPS on TNF-a release by RA FLS and THP-1 cells. A. IL-6 release was determined by ELISA in culture supernatants
harvested 3 h, 6 h and 24 h after stimulation with LPS (1 mg/ml) or medium (C). B, C. TNF-a release by RA FLS and THP-1 cells was determined by
ELISA in culture supernatants harvested 3 h, 6 h and 24 h after stimulation with LPS or medium (C). Data are expressed as the mean of triplicate
samples 6 SD and are representative of three independent experiments. D. TNF-a expression was determined by western-blotting with anti-TNF-a
antibodies in RA FLS, 3 h, 6 h and 24 h after stimulation with LPS or medium (C). Recombinant TNF-a was used as control. For protein loading control,
membranes were reprobed with anti-b-actin antibodies. Data are expressed as the mean of triplicate samples +/2 SD of three independent
experiments for each patient.
doi:10.1371/journal.pone.0019827.g001
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LPS induced synthesis of TNF-a mRNA in RA FLS
We then examined the effect of LPS treatment on TNF-a
mRNA accumulation in FLS. RT-PCR was performed with
RNA isolated from FLS either non-activated or activated with
1 mg/ml LPS for 2 h, 4 h and 6 h. No constitutive expression of
TNF-a mRNA was detectable in control cells, whereas LPS
treatment of FLS resulted in a detectable accumulation of TNF-
a mRNA within 2 h (Figure 2A). Expression of TNF-a mRNA
in FLS was similar to that in THP-1 cells, where TNF-a is
normally expressed after LPS treatment (Figure 2B). To
investigate the mechanisms responsible for the lack of TNF-a
protein synthesis in LPS-activated FLS, cells were incubated with
LPS for 3 h and then for another 1 to 4 h with 5 mg/ml
actinomycin D. After 1 h of actinomycin D treatment, TNF-a
mRNA became undetectable in LPS-activated FLS (Figure 2C)
but not in LPS-activated THP-1 cells, where the mRNA
accumulation decreased but was still detectable after 1 and 2 h
of actinomycin D treatment (Figure 2D). These results indicate
that de novo synthesized TNF-a mRNA is unstable in LPS-
activated FLS.
TNF-a synthesis is not repressed by miR-125b and miR-
939 in LPS-activated RA FLS
Using a DNA microarray, we identified two upregulated
miRNAs in LPS-treated cells compared to control cells: miR-
125b (2.3 fold) and miR-939 (6.1 fold). We confirmed the
induction of miR-125b and miR-939 expression by quantitative
RT-PCR analysis. The mean increase was 2 and 7 times for miR-
125b and miR-939 respectively, after 6 h of LPS-activation
(Figure 3A). Similar experiments were performed in THP-1 cells
as control, and no changes in the expression of these miRNAs
were observed. Since these two miRNAs were predicted to target
TNF-a mRNA, we studied the functional consequence of their
inhibition by antisense oligonucleotides on TNF-a release by LPS-
activated RA FLS. As shown in Figure 3B, transfection of miR-
125b and miR-939 antisense molecules impaired endogenous
miRNAs expression as compared to miR-125b and mir-939
expression in activated cells transfected with a control antisense
oligonucleotide. We next tested whether inhibition of miR-125b
and miR-939 affected TNF-a protein release in LPS-activated
FLS. We transfected FLS for 24 h with antisense oligonucleotides
and then measured TNF-a release by LPS-stimulated FLS. As
illustrated in Figure 3C, treatment with LPS did not restore TNF-
a release by activated RA FLS transfected with antisense
oligonucleotides targeting miR-125b, miR-939 or with a combi-
nation of these two inhibitors (Figure 3C). No significant effect of
antisense oligonucleotides transfection on cell viability was
observed, as determined by MTT assay (data not shown). In
addition, the transfection of antisense oligonucleotides did not
impair FLS activation since FLS transfected with targeting and
non-targeting miRNA inhibitors still produced IL-6 after 6 h of
activation with LPS (Figure 3D).
Finally, transfection of antisense oligonucleotides did not restore
intracellular or membrane bound TNF-a (Figure 3E). Taken
together these data demonstrate that miR-125b and miR-939 are
not implicated in the down-regulation of TNF-a synthesis in LPS-
activated FLS.
Inhibition of miR-346 stabilizes TNF-a mRNA but does
not induce TNF-a release from LPS-activated RA FLS
We previously showed that miR-346 which is overexpressed in
LPS-activated FLS, inhibited Btk expression [25]. As Btk is
implicated in TNF-a mRNA stabilization, we therefore hypoth-
esized that the inhibition of Btk expression in RA FLS by miR-346
could result in the subsequent instability of TNF-a mRNA and
therefore lack of TNF-a release.
We first confirmed that miR-346 is overexpressed in FLS but
not in THP-1 cells in response to LPS (Figure 4). We then
Figure 2. Effect of LPS on TNF-amRNA expression in RA FLS and THP-1 cells. A, B. TNF-a mRNA expression was determined by RT-PCR in
RA FLS (A) and THP-1 cells (B) stimulated with LPS (1 mg/ml) for 2 h, 4 h and 6 h. Control cells were incubated for 4 h with medium (C). C, D. RA FLS
and THP-1 cells were stimulated for 3 h with LPS and then incubated for another 1, 2, 3 and 4 h with actinomycin D (5 mg/ml). Control cells were
incubated for 3 h with medium. TNF-amRNA expression was determined by RT-PCR. The results are representative of three different experiments for
each patient.
doi:10.1371/journal.pone.0019827.g002
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monitored the fate of the TNF-a mRNA in RA FLS transfected
with miR-346 antisense oligonucleotides or control antisense
oligonucleotides and treated first with LPS for 3 h and then with
actinomycin D for another 1, 2, 3 and 4 h. As opposed to the
control, we observed a stabilization of TNF-a mRNA after
actinomycin D treatment in LPS-activated FLS transfected with
miR-346 antisense molecules (Figure 5A). These results indicate
that miR-346 plays a role in the control of the stability of TNF-a
mRNA. Moreover, we found, using intracellular Elisa, that
transfection of FLS with antisense oligonucleotides targeting
miR-346, led to the accumulation of intracellular TNF-a after
activation with LPS for 6 h. No effect was observed in cells that
were not transfected or transfected with a control oligonucleotide
(Figure 5B). This result was confirmed by western blotting
analysis using anti-TNF-a antibodies (Figure 5C). Nevertheless,
treatment with LPS surprisingly did not restore TNF-a release
(Figure 5D) or TNF-a membrane expression (data not shown) in
activated RA FLS transfected with antisense oligonucleotides
targeting miR-346.
miR-346 and Btk regulate TNF-a release in LPS-activated
THP-1 cells
We next tested whether miR-346, which inhibits Btk
expression in THP-1 cells [25], could impair TNF-a release
from THP-1 cells and act as an anti-inflammatory agent in these
cells. We thus examined TNF-a release by THP-1 cells
stimulated with LPS and pretreated with Leflunomide metabolite
analog (LFM-A13), a known inhibitor of Btk. In these conditions,
LPS-induced TNF-a production was strongly inhibited when
compared with cells not treated with the inhibitor (Figure 6A).
These results demonstrate that TNF-a release is Btk-dependent in
THP-1 cells.
We next tested whether the transient expression of miR-346
affected TNF-a release in LPS-activated THP-1 cells. We
transfected THP-1 cells with miR-346 mimic and, 24 h later,
measured TNF-a release after 3 and 6 h of LPS stimulation. As
illustrated in Figure 6B, cells transfected with miR-346 mimic
showed a significant decrease of TNF-a release compared to cells
transfected with the control miRNA mimic. Altogether, these
Figure 3. Effect of transfection of miRNA antisense molecules on TNF-asynthesis by RA FLS. A, B. MiR-125b and miR-939 levels were
determined by quantitative RT-PCR in RA FLS and THP-1 cells stimulated with LPS for 3 h and 6 h. RNAU6 was used as endogenous control for data
normalization. The control (C) corresponded to untreated cells. RA FLS were transfected with either miR-125b or miR-939 antisense molecules or in
combination or with the Clear-miRTM negative control (control). LPS or medium (C) activation of transfected cells was performed 24 h post-
transfection, for 3 h and 6 h. Non transfected RA FLS were used as negative controls (NT). C, D. TNF-a and IL-6 release were determined by ELISA in
culture supernatants harvested 6 h after stimulation with LPS or medium (C). E. Intracellular TNF-a expression was determined in transfected FLS and
activated with LPS for 24 h. Data are expressed as the mean of triplicate samples +/2 SD of three independent experiments for each patient.
doi:10.1371/journal.pone.0019827.g003
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results confirm that miR-346 participates in the control of TNF-a
release in both FLS and THP-1 cells.
Btk regulates TNF-a synthesis and release in LPS-
activated FLS and THP-1 cells by controlling TTP
expression
Given the prominent role played by TTP in mRNA decay, we
looked into the involvement of Btk on the control of TTP
expression. To that end, we transfected THP-1 cells with miR-346
mimic for 24 h and measured TTP mRNA expression after
stimulation with LPS for 2 and 4 h. As illustrated in Figure 7A,
cells transfected with miR-346 mimic showed a significant increase
in TTP expression compared to cells transfected with the control
miRNA mimic. We also examined TTP mRNA expression by
THP-1 cells pretreated with LFM-A13 before LPS stimulation. In
this condition, TTP production by LPS-treated cells was also
strongly upregulated compared with non-treated cells (Figure 7B).
We next tested whether inhibition of miR-346 affected TTP
expression in LPS-activated RA FLS. We transfected miR-346
specific or control antisense oligonucleotides in RA FLS and
treated the cells 48 h later with LPS for 2 and 4 h. We observed a
decrease of TTP mRNA expression in the presence of miR-346
antisense oligonucleotides but not with control oligonucleotides
(Figure 7C).
To further confirm that miR-346 regulated TNF-a synthesis by
controlling TTP expression, we co-transfected THP-1 cells with
miR-346 mimic and a siRNA targeting TTP for 48 h and
measured TNF-a mRNA expression and cytokine release by
transfected cells stimulated with LPS. As illustrated in Figure 7 (D,
E), treatment of THP-1 cells with a siRNA targeting TTP
stabilized TNF-a mRNA and restored TNF-a release by cells co-
transfected with miR-346 mimic as compared to cells transfected
with miR-346 mimic alone.
Taken together, these results demonstrate that miR-346 and Btk
are implicated in the regulation of LPS-induced TTP expression,
which in turn controls TNF-a mRNA stability and TNF-a release.
Discussion
As opposed to other cells from the synovial membrane, PRRs-
activated FLS fail to release TNF-a. This study was aimed at
identifying miRNAs that might be involved in the control of TNF-
a release. Our results establish that miR-346 can act as a negative
regulator of TNF-a release in RA FLS in response to LPS, by
inhibiting transcription of the Btk gene. Moreover, since
transfection of miR-346 in macrophages also inhibits TNF-a
release induced by LPS, these data are a strong indication that
miR-346 plays a global role in the control of the inflammatory
response.
In an initial attempt to identify miRNAs involved in the control
of TNF-a release, we performed a miRNAs microarray analysis of
LPS-activated FLS. miR-125b and miR-939 were strongly
induced after LPS treatment, and both were predicted to target
TNF-a. This finding correlated well with results from Tili et al.
[22], who showed that LPS activation of mouse Raw 264.7
macrophages down regulated miR-125b, which allowed TNF-a
synthesis by activated macrophages. This result was also in
agreement with the fact that overexpression of miR-125b leads to
a significant inhibition of the ERK 1/2 pathway without affecting
ERK 1/2 levels consistent with the idea that this miRNA acts
upstream of ERK [26]. However, inhibition of both miRNAs with
antisense nucleotides was not able to restore either TNF-a
intracellular expression or release by LPS-activated FLS. Our
results suggest that the inhibition of these miRNAs is not sufficient
to override the negative regulatory effect induced by LPS signaling
on TNF-a release in FLS. Another non-exclusive possibility would
be that they may act in FLS in cooperation with other factors.
Previous studies from our laboratory [25], showed that LPS also
induces the expression of miR-346 in LPS-activated RA FLS and
that this miRNA regulates negatively IL-18 release by inhibiting
Btk expression. Btk is involved in the stabilization of various
cytokines mRNAs, including the TNF-a mRNA [27]. Moreover
TLR2-mediated stimulation of XLA mononuclear cells resulted in
impaired production of TNF-a and IL-1b while IL-6, IL-8 and IL-
Figure 4. Quantitative RT-PCR analysis of miR-346 expression in LPS-activated RA FLS and THP-1 cells. MiR-346 level was determined
by quantitative RT-PCR in RA FLS and THP-1 cells stimulated with LPS (1 mg/ml) for 3 h and 6 h. U6 small nuclear RNA (RNAU6) was used as
endogenous control for data normalization. The control (C) corresponded to untreated cells. Data are expressed as the mean of triplicate samples
+/2 SD of three independent experiments for each patient.
doi:10.1371/journal.pone.0019827.g004
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10 remained unaffected through a pathway involving the p38
MAPK [28]. Similar results were observed with dendritic cells
from the same patients; stimulation with TLR2, TLR4, TLR7/8
and TLR3 ligands results in lower release of TNF-a IL-6 and IL-
12 production was unaffected [29]. On the contrary, in murine
bone marrow-derived mast cells, Btk is dispensable in LPS- or
lipopeptide-induced secretion of IL-6 and TNF-a [30]. FLS
express the epithelial and endothelial tyrosine kinase (Etk), which is
implicated in IL-6 and IL-8 release [31], but they fail to express
either Btk mRNA or the mature protein constitutively or after LPS
activation. Our results established that in FLS, inhibition of miR-
346 expression resulted i) in stabilization of TNF-a mRNA and ii)
intracellular expression of the mature protein. However this was
not sufficient to override completely the inhibition of TNF-a
release in cell supernatants. The fact that TNF-a is neither
expressed at the cell surface nor secreted indicates that additional
mechanisms exist to regulate TNF-a release from activated FLS.
There are multiple transport pathways to the cell surface, which
depend on the individual cargo. Recently, Lieu et al. showed that
secretion of TNF-a in LPS-activated macrophages is controlled by
a trans-Golgi network golgin, p230 which is mobilized in response
to LPS [32]. It is possible that in RA FLS this mechanism is
compromised and additional experiments are now required to
resolve this possibility.
Further investigations revealed that LFMA-13, a Btk inhibitor,
inhibited TNF-a secretion in THP-1 cells. This result was
consistent with other reports, which demonstrated that LFMA-
13 inhibited the activation of NF-kB by LPS in THP-1 cells [33].
Moreover, we also demonstrated that transfection of miR-346
mimic in THP-1 cells strongly diminished TNF-a release. As we
previously showed that miR-346 inhibits Btk expression in THP-1
cells by an indirect mechanism probably involving yet undefined
transcription factors, we propose that in THP-1 cells, the control
of TNF-a release by miR-346 involves the inhibition of Btk
expression. At present the details of the mechanism that mediate
the effect of Btk on TNF-a mRNA stability are unclear.
Arsivatham et al. indicated that the components of the ARE-
mediated decay pathway are heavily targeted by miRNAs [34]. It
appears that ARE control of TNF-a expression may operate at
multiple post-transcriptional levels including the miRNAs regula-
tion of ARE-binding proteins.
Among the many ARE-binding proteins that target TNF-a,
TTP has emerged as a primary player as it was shown to promote
its mRNA lability [11]. As a matter of fact, TTP knocked-out mice
Figure 5. Effect of transfection of miR-346 antagomirs on TNF-a mRNA stability and release in RA FLS. A. FLS were transfected with
miR-346 antisense molecules or with the Clear-miRTM negative control (control), activated with LPS 24 h post-transfection for 3 h and incubated for
another 1, 2, 3 and 4 h with actinomycin D. Control cells were incubated for 3 h with medium (C). NT: non transfected cells. B, C: TNF-a expression
was detected using cellular ELISA or western blotting with anti-TNF-a antibodies, in FLS transfected with miR-346 antisense molecules or with the
Clear-miRTM negative control (control) or in non transfected FLS (NT). 24 h post-transfection, FLS were either incubated in medium (C) or activated
with LPS for 6 h. The results are representative of three different experiments for each patient. D. TNF-a release was determined by ELISA in culture
supernatants after stimulation with LPS or medium (C). Data are expressed as the mean of triplicate samples +/2 SD of three independent
experiments for each patient. p,0.01.
doi:10.1371/journal.pone.0019827.g005
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show elevated levels of TNF-a production in response to LPS [12].
The question naturally arose whether Btk would be implicated in
TTP expression. We showed that transfection of miR-346
antisense oligonucleotides decreased TTP mRNA expression in
LPS-activated RA FLS. Furthermore, we also demonstrated that
Btk inhibition by either LFM-A13 or miR-346 mimic transfection
increased TTP mRNA accumulation in LPS-activated THP-1
cells. These results suggest that stabilization of TNF-a mRNA by
Btk is mediated by down-regulation of TTP.
We therefore propose a model of regulation of TNF-a release in
which LPS induces TNF-a mRNA, miR-346 and TTP expression
in FLS. Inhibition of Btk expression by miR-346 would then
enable stabilization of TTP expression and would therefore result
in the rapid decay of TNF-a mRNA. Blocking Btk either
chemically (with the inhibitor LFM-A13), or by overexpressing
miR-346 (in THP-1 cells), would therefore result in the inhibition
of TNF-a secretion (Figure 8A, B). Taken together, our data
indicate an important role for miR-346 in the regulation of TNF-a
release by controlling Btk which in turn regulates TTP expression.
In conclusion, our findings provide clear evidence that miR-346
which is induced by bacterial ligands can act as a negative
regulator of inflammation in human.
Materials and Methods
Reagents
Cell culture media (RPMI 1640, M199 and DMEM), fetal calf
serum (FCS), L-glutamine, penicillin, streptomycin, amphotericin
B, TRIzol reagent were from Invitrogen (Cergy-Pontoise, France).
LPS from Salmonella abortus equi and type XI collagenase,
actinomycin D, LFMA-13 and anti-b-actin mouse IgG monoclo-
nal antibodies were obtained from Sigma (Saint-Quentin-Falla-
vier, France). The Lightcycler Faststart DNA Master SYBR Green
I was from Roche Applied Science (Penzberg, Germany). The
miScript System was obtained from Qiagen (Courtabeuf, France).
Clear-miRTMmiRNA inhibitors were from Eurogentec (Seraing,
Belgium). MiRIDIANH miR-346 mimic and miRIDIAN miRNA
mimic negative control and siRNATTP were supplied by
Dharmacon (Brebieres, France). Human Dermal Fibroblast
NucleofectorTM kit and Cell Line Nucleofector Kit V were from
Amaxa (Cologne, Germany). The enzyme immunoassay kits for
human TNF-a´ detection and for human IL-6 detection were from
R&D (Lille, France). Anti-Btk mouse IgG monoclonal antibodies
were from BD Transduction Laboratories (Le Pont de Claix,
France) and anti-TNF-a mouse monoclonal antibodies were from
Figure 6. Effect of transfection of miR-346 mimic on TNF-a release by THP-1 cells. A. TNF-a release by THP-1 cells preincubated or not
(control) with LFMA-13 (172 mM) for 1 h and then stimulated with LPS or medium (C) for 3 and 6 h, was evaluated by ELISA. B. THP-1 cells were
transfected with miR-346 mimic or with the miRNA mimic negative control (control) and activated 24 h post-transfection with either LPS or medium
(C) for 3 and 6 h. TNF-a release was evaluated by ELISA. Data are expressed as the mean of triplicate samples +/2 SD of three independent
experiments for each patient. p,0.01.
doi:10.1371/journal.pone.0019827.g006
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Santa Cruz Biotechnology (Heidelberg, Germany). Throughout
this study, buffers were prepared with apyrogenic water obtained
from Braun Medical (Boulogne, France). The microarray data
were submitted to the Minimum Information About Microarray
Experiment (MIAME) database with the accession number E-
MEXP-1970.
Cell culture
Human FLS were isolated from synovial tissues from four
different RA patients at the time of knee joint arthroscopic
synovectomy as described previously after informed consent was
obtained from patients [35]. The diagnosis was conformed to the
revised criteria of the American College of Rheumatology [36].
Informed consent was provided according to the Declaration of
Helsinki and obtained from all patients. Approval by the ethical
committee of the Hopitaux Universitaires de Strasbourg was
obtained. FLS cultures were done as previously described [37].
Experiments were performed between the 3rd and the 9th passage.
During that time, cultures were constituted of a homogeneous
population of fibroblastic cells, negative for CD16 as determined
by FACS analysis. Cell number and cell viability were checked by
the MTT test (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide test) as described elsewhere [38]. THP-1 cells
(no. 88081201, European collection of cell cultures, Salisbury,
UK) were cultured as described previously [39].
Cell activation
FLS (5.105 cells) and THP-1 cells (107 cells) cells were stimulated
with 2 ml of medium alone or medium containing LPS (1 mg/ml)
for 3 h, 6 h and 24 h. After stimulation, supernatants were
harvested and assayed for cytokine contents using commercially
available ELISA tests for human IL-6 and TNF-a.
Stimulation of cells for total extraction
Total RNA was extracted from human FLS (106 cells) or THP-1
cells (107 cells) incubated for 2 h, 4 h and 6 h with 2 ml of
Figure 7. MiR-346 regulates the expression,of TTP in activated RA FLS and THP-1 cells. A, B: TTP mRNA levels were determined using
quantitative RT-PCR in LPS-activated THP-1 cells transfected with miR-346 antisense molecules or preincubated for 1 h with LFMA-13. C: TTP mRNA
levels were determined using quantitative RT-PCR in LPS-activated RA-FLS transfected with miR-346 antisense molecules Results were normalized to
GAPDH and expressed as fold change compared with samples from cells incubated in medium (C). D, E: THP-1 cells were transfected with miR-346
mimic, with miR-346 mimic and siRNATTP or with a negative control (control) and activated 48 h post-transfection with either LPS or medium (C).
TNF-a mRNA levels were determined using RT-PCR and TNF-a release was evaluated by ELISA. Data are expressed as the mean of triplicate samples
+/2 SD of three independent experiments for each patient.
doi:10.1371/journal.pone.0019827.g007
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medium alone or medium containing LPS (1 mg ml) using TRIzol
according to the manufacturer’s instructions.
Total RNA isolated from FLS and THP-1 cells was reverse
transcribed using the First-Strand cDNA Synthesis Kit according
to the manufacturer’s instructions (In Vitrogen) and amplified. For
TNF-a, after an initial denaturing at 95uC for 5 min, the
temperatures used were 95uC for 30 s, 57uC for 30 s and 72uC
for 2 min followed by an extension of 5 min at 72uC. For b-actine,
after an initial denaturing at 94uC for 5 min, the temperatures
used were 94uC for 1 min, 56uC for 45 s and 72uC for 1 min
followed by an extension of 5 min at 72uC. PCR products were
separated in 2% agarose gels and visualized with ethidium
bromide. The primers used were: (i) TNF-a: 59- AGC-ACT-
GAA-AGC-ATG-ATC-CGG-39 and 59- CAT-GGG-CTA-CAG-
GCT-TGT-CAC-39; and (ii) b-actin: 59-CCA-ACC-GCG-AGA-
AGA-TGA-CC-39and 59-GAT-CTT-CAT-GAG-GTA-GTC-
AGT-39.
Real-time quantitative RT-PCR
Quantitative RT-PCR analyses for miRNAs were performed
using the miScript System and the primers (Qiagen). RNA
concentrations were determined with a NanoDrop instrument
(NanoDrop Technologies). Reverse transcriptase reactions and
quantitative RT-PCR were performed according to the manufac-
turer’s protocols. A U6 endogenous control was used for
normalization. All reactions were run in triplicate in a Lightcycler
Instrument (Roche Applied Science). Relative expression was
calculated using the comparative threeshold cycle (Ct) method. All
reactions were run in triplicate in a using a Rotor-GeneTM 6000 real-
time PCR machine (Corbett Life ScienceH, Sydney, Australia). Relative
expression was calculated using the comparative threeshold cycle
(Ct) method.
Total RNA isolated from FLS was reverse transcribed using the
First Strand cDNA Synthesis Kit according to the manufacturer’s
instructions (In Vitrogen). Real-time quantitative RT-PCR was
performed in a total volume of 20 ml using a SensiMix Plus
SYBRH (Quantace, Corbett Life ScienceH, Sydney, Australia), and
gene specific primers:
GAPDH: 59-GGTGAAGGTCGGAGTCAACGGA-39
and 59-GAGGGATCTCGCTCGCTCCTGGAAGA-39
TTP: 59-TCGGGACCCTGGAGCCTGAG-39.
and 59 -AGCCAGCGGTGCGAAGCC-39
TTP and GAPDH were reverse transcribed and amplified.
Amplification products were detected as an increased fluorescent
signal of SYBRHGreen during the amplification cycles. Results
were obtained using SDS Software (Perkin Elmer) and evaluated
using Excel (Microsoft). Melting-curve analysis was performed to
assess the specificity of PCR products.
Transfections
The Clear-miR anti-miR-125b, anti-miR-939 and anti-miR-
346 used in our study were designed to inhibit efficiently the
activity of miR-125b, miR-939 and miR-346. They consist of a
sequence of 21 nucleotides complementary to the miRNA.
Transient transfection of FLS with Clear-miRTM miRNA
inhibitors (200 nM) was performed using the Human Dermal
Fibroblast NucleofectorTM kit from Amaxa as previously described
[26]. Transient transfection of THP-1 cells with the miR-346
mimic (200 nM) or with miR-346 mimic and siRNATTP was
performed using the Cell Line Nucleofector Kit V from Amaxa.
FLS and THP-1 cells were then plated in 24-well plates (2.105 cells
per well and 106 cells per well respectively). All assays were
performed 24 h for miR-346 mimic and 48 h for siRNATTP,
post-transfection. Controls were carried out with the Clear-miRTM
negative control or with the mimic miRNA negative control.
Transfection efficiency was evaluated with the PmaxGFP vector.
Cell numbers and cell viability were assessed using the MTT
test. TNF-a release was measured in culture supernatants by a
Figure 8. Model of action for miR-346 and Btk in the regulation of TNF-a secretion. See text for details.
doi:10.1371/journal.pone.0019827.g008
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heterologous two-site sandwich ELISA according to the manu-
facturer’s instructions.
Western Blot
106 cells (FLS) were incubated for various times (3 h, 6 h and
24 h) with LPS (1 mg/ml). Controls were performed with cells
maintained in medium with 5% heat inactivated FCS for 6 h.
After stimulation, cells were centrifuged and the pellets were
suspended 20 min on ice in 300 mL of ice-cold lysis buffer (1%
Triton X-100, 20 mM Tris-HCl pH 8.0, 130 mM NaCl, 10%
glycerol, 1 mM sodium orthovanadate, 2 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, and protease inhibitors). Lysates
were centrifuged for 10 min at 14,000 g at 4uC and supernatants
were subjected to SDS-PAGE and transferred electrophoretically
to nitrocellulose membranes. Membranes were blocked using 1%
bovine serum albumin in TBS (20 mM Tris, pH 7.5, 150 mM
NaCl) for 1 h at 25uC. The blots were incubated with mouse anti-
TNF-a IgG monoclonal antibodies for 2 h at 25uC followed by
incubation with horseradish peroxidase-conjugated goat anti-
mouse IgG monoclonal antibodies (1 h at 25uC) and detected by
enhanced chemiluminescence (Super Signal West Femto Maxi-
mum Sensitivity Substrate, Pierce) according to the manufacturer’s
instructions. To confirm the presence of equal amounts of
proteins, bound antibodies were removed from the membrane
by incubation in 62.5 mM Tris, pH 6.7, 100 mM b-mercapto-
ethanol, 2% SDS for 30 min at 50uC and reprobed again with anti
b-actin (clone AC-74, Sigma) mouse monoclonal antibodies.
Detection of cellular TNF-a
Transfected FLS (2.104 cells) with miR-125b, miR-939 and
miR-346 antisense oligonucleotides, were seeded into 96-well
plates and then incubated 24 h post-transfection in 200 ml of
complete medium containing LPS, (1 mg/ml) for 6 h. Cells were
fixed with 4% paraformaldehyde in PBS pH 7.4 for 20 min. Free
aldehyde groups were quenched with NH4Cl 50 mM in PBS
pH 7.4 for 20 min. Non specific binding was blocked by
incubation in PBS containing either 0,2% bovine serum albumin
or 0,2% bovine serum albumin and 0.05% saponin for 30 min at
37uC. The cells were then incubated with biotinylated anti-TNF-a
antibodies for 2 h. Absorbance was measured at 450 nm.
Statistical analysis
Statistical analysis was performed using Student’s t-test. Values
were compared between different groups in the experiment. P
values less than 0.05 were considered statistically significant.
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